CR20150591A - Derivados de triazina - Google Patents

Derivados de triazina

Info

Publication number
CR20150591A
CR20150591A CR20150591A CR20150591A CR20150591A CR 20150591 A CR20150591 A CR 20150591A CR 20150591 A CR20150591 A CR 20150591A CR 20150591 A CR20150591 A CR 20150591A CR 20150591 A CR20150591 A CR 20150591A
Authority
CR
Costa Rica
Prior art keywords
triazine derivatives
compounds
following formula
relates
present
Prior art date
Application number
CR20150591A
Other languages
English (en)
Inventor
Thomas Allen Chappie
Christopher John Helal
Bethany Lyn Kormos
Jamison Bryce Tuttle
Patrick Robert Verhoest
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CR20150591A publication Critical patent/CR20150591A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a una nueva clase de derivados de triazina, como se describen en la siguiente Fórmula I, en donde A, X, R1, R2, R3 y R4 son como se definen en la presente, y al uso de los compuestos como inhibidores de PDE10.
CR20150591A 2013-05-02 2015-10-27 Derivados de triazina CR20150591A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818650P 2013-05-02 2013-05-02
PCT/IB2014/060945 WO2014177977A1 (en) 2013-05-02 2014-04-23 Imidazo-triazine derivatives as pde10 inhibitors

Publications (1)

Publication Number Publication Date
CR20150591A true CR20150591A (es) 2016-01-04

Family

ID=50841902

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150591A CR20150591A (es) 2013-05-02 2015-10-27 Derivados de triazina

Country Status (34)

Country Link
US (3) US8933224B2 (es)
EP (1) EP2991989B1 (es)
JP (1) JP6263606B2 (es)
KR (1) KR101770905B1 (es)
CN (1) CN105164134B (es)
AP (1) AP2015008843A0 (es)
AR (1) AR096161A1 (es)
AU (1) AU2014261070A1 (es)
BR (1) BR112015027760A8 (es)
CA (1) CA2910759C (es)
CL (1) CL2015003037A1 (es)
CR (1) CR20150591A (es)
CU (1) CU20150144A7 (es)
DK (1) DK2991989T3 (es)
DO (1) DOP2015000271A (es)
EA (1) EA027936B1 (es)
EC (1) ECSP15050110A (es)
ES (1) ES2637816T3 (es)
GE (1) GEP201706675B (es)
HK (1) HK1213885A1 (es)
MA (1) MA38559B1 (es)
MD (1) MD20150103A2 (es)
MX (1) MX2015015163A (es)
NI (1) NI201500157A (es)
NZ (1) NZ712949A (es)
PE (1) PE20151940A1 (es)
PH (1) PH12015502462A1 (es)
SG (1) SG11201508201VA (es)
TN (1) TN2015000490A1 (es)
TW (1) TWI508966B (es)
UA (1) UA111696C2 (es)
UY (1) UY35547A (es)
WO (1) WO2014177977A1 (es)
ZA (1) ZA201508968B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014261070A1 (en) * 2013-05-02 2015-10-29 Pfizer Inc. Imidazo-triazine derivatives as PDE10 inhibitors
KR102411532B1 (ko) 2016-09-09 2022-06-22 노파르티스 아게 엔도솜 톨-유사 수용체의 억제제로서의 화합물 및 조성물
BR112022007491A2 (pt) * 2019-10-21 2022-07-12 Sk Biopharmaceuticals Co Ltd Medicamento, composição farmacêutica e método para prevenção, alívio ou tratamento de distúrbio cognitivo, e, uso de um composto de imidazopirimidina ou imidazotriazina

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
US8207370B2 (en) 2006-09-26 2012-06-26 Kaneka Corporation Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2009025785A2 (en) 2007-08-21 2009-02-26 Merck & Co., Inc. Cb2 receptor ligands for the treatment of pain
DE102007059723A1 (de) 2007-12-12 2009-06-18 Siemens Medical Instruments Pte. Ltd. Hörvorrichtung mit Batterieklappenmodul
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
EP2288611B1 (en) 2008-03-20 2013-05-15 Amgen Inc. Aurora kinase modulators and method of use
NZ599597A (en) * 2009-10-30 2013-05-31 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
WO2011089400A1 (en) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
AR080754A1 (es) * 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
KR20130083389A (ko) 2010-05-28 2013-07-22 바이오크리스트파마슈티컬즈,인코포레이티드 야누스 키나아제 억제제로서 헤테로사이클릭 화합물
EP2582681A1 (en) 2010-06-17 2013-04-24 Novartis AG Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
SG192576A1 (en) 2011-02-23 2013-09-30 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
AU2014261070A1 (en) * 2013-05-02 2015-10-29 Pfizer Inc. Imidazo-triazine derivatives as PDE10 inhibitors

Also Published As

Publication number Publication date
KR20160003234A (ko) 2016-01-08
CL2015003037A1 (es) 2016-04-22
JP2016517877A (ja) 2016-06-20
PE20151940A1 (es) 2016-01-21
CA2910759C (en) 2018-01-16
MD20150103A2 (ro) 2016-02-29
MX2015015163A (es) 2016-02-22
AU2014261070A1 (en) 2015-10-29
TWI508966B (zh) 2015-11-21
DK2991989T3 (en) 2017-07-31
EA201591819A1 (ru) 2016-05-31
PH12015502462A1 (en) 2016-02-22
UA111696C2 (uk) 2016-05-25
CU20150144A7 (es) 2016-04-25
US8933224B2 (en) 2015-01-13
US20140329820A1 (en) 2014-11-06
NI201500157A (es) 2015-11-30
US9145427B2 (en) 2015-09-29
ECSP15050110A (es) 2017-08-31
WO2014177977A1 (en) 2014-11-06
TN2015000490A1 (fr) 2017-04-06
EA027936B1 (ru) 2017-09-29
ZA201508968B (en) 2017-11-29
CA2910759A1 (en) 2014-11-06
SG11201508201VA (en) 2015-11-27
MA38559B1 (fr) 2018-04-30
JP6263606B2 (ja) 2018-01-17
AP2015008843A0 (en) 2015-11-30
AR096161A1 (es) 2015-12-09
KR101770905B1 (ko) 2017-08-23
DOP2015000271A (es) 2016-02-29
US20150080401A1 (en) 2015-03-19
UY35547A (es) 2014-11-28
ES2637816T3 (es) 2017-10-17
US20150353579A1 (en) 2015-12-10
US9296761B2 (en) 2016-03-29
NZ712949A (en) 2017-04-28
CN105164134A (zh) 2015-12-16
EP2991989B1 (en) 2017-06-28
BR112015027760A8 (pt) 2018-05-08
GEP201706675B (en) 2017-05-25
CN105164134B (zh) 2017-09-22
TW201506027A (zh) 2015-02-16
HK1213885A1 (zh) 2016-07-15
EP2991989A1 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
DOP2017000267A (es) Amidas heterocíclicas como inhibidores de quinasa
DOP2018000089A (es) Amidas heterocíclicas como inhibidores de cinasas
CU24309B1 (es) Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
CR20150447A (es) Nuevos derivados de pirazol
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
UY35762A (es) Uso de picolinamidas macrocíclicas como fungicidas
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CR20160076A (es) NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CR20150250A (es) Nuevos derivados de piridina
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
UY34301A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
CR20150061A (es) Compuesto de pirazolopirimidinas
DOP2015000059A (es) Amino-quinolinas como inhibidores de cinasa
CR20150440A (es) Nuevos derivados de piridina
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
EA201590688A1 (ru) Производные n-проп-2-инилкарбоксамида и их применение в качестве антагонистов trpa1
PE20151145A1 (es) Piridopirazinas sustituidas como inhibidores de syk
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
ECSP15050110A (es) Derivados de triazina
CR20160146A (es) Derivados de urea indol sustituido con glucopiranosil y su uso como inhibidores sglt
CR20150073A (es) Nuevos derivados de piridina